| Title | Use of aromatase inhibitors in children and adolescents with disorders of growth and adolescent development. | | Author(s) | Shulman DI, Francis GL, Palmert MR, Eugster EA, Lawson Wilkins Pediatric Endocrine Society Drug and Therapeutics Committee | | Institution | All Children's Hospital, St Petersburg, Florida 33701, USA. dshulman@health.usf.edu | | Source | Pediatrics 2008 Apr; 121(4):e975-83. | | MeSH | Adolescent
Age Factors
Aromatase Inhibitors
Body Height
Bone Density
Bone Development
Child
Child Development
Child, Preschool
Female
Growth Disorders
Gynecomastia
Humans
Male
Prognosis
Puberty, Precocious
Risk Assessment
Sensitivity and Specificity
Sex Factors
Sexual Maturation
| | Abstract | Although treatment of children and adolescents who have disorders of growth and adolescent development with aromatase inhibitors is increasingly common, data for or against their use are extremely limited. Precocious puberty, short stature, and gynecomastia are conditions for which inhibition of the enzyme aromatase might prove beneficial to reduce clinical signs of estrogenization and/or estrogen-mediated skeletal maturation. In this report, we summarize the published data regarding the use of aromatase inhibitors in these conditions, and review known and potential benefits, safety concerns, and shortcomings of the available information. | | Language | eng | | Pub Type(s) | Journal Article
Review
| | PubMed ID | 18381525 |
|
